Friday, January 31, 2025
spot_img

Director/PDMR Shareholding

DXS INTERNATIONAL PLC

(AQSE: DXSP)

Notification of Director / PDMR Dealing

DXS INTERNATIONAL PLC

The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 30 January, Mr Bob Sutcliffe, the Chairman, purchased 15,000 Ordinary Shares in the Company at a price of 2.9p per share.

Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,253,756 Ordinary Shares representing 1.96% of the issued share capital of the Company.

1

 

Details of the person discharging managerial responsibilities / person closely associated
a)

 

Name

 

Mr. Robert Sutcliffe

 

2 Reason for the notification
a)

 

Position/status

 

Chairman
b)

 

Initial notification /Amendment

 

Initial
3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

DXS INTERNATIONAL PLC
b)

 

LEI

 

 

2138001R1KEUWTXEVJ44
4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

 

 

 

 

Description of the financial instrument, type of instrument Ordinary Shares of 0.33p each
   
Identification code ISIN GB00B2Q6HZ92
   
b)

 

Nature of the transaction

 

Purchase of shares
c)

 

 

 

 

Price(s) and volume(s)        
    Price(s) Volume(s)  
    2.9p

15,000

 
d)

 

 

 

 

 

 

Aggregated information  
   
– Aggregated volume  
   
– Price  
   
e)

 

Date of the transaction

 

 

30 January 2025
f)

 

Place of the transaction

 

 

Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman
DXS International plc
www.dxs-systems.com

01252 719800
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Powered by SlickText.com

Hot this week

IES Holdings Acquires Arrow Engine Company

HOUSTON, Jan. 31, 2025 (GLOBE NEWSWIRE) --...

Airship AI Secures Follow-On Seven-Figure Contract Award with Fortune 100 Transportation & E-Commerce Company

Acropolis Enterprise Video and Data Management Platform Supports Operational...

Global Water Resources Declares Monthly Dividend

PHOENIX, Jan. 31, 2025 (GLOBE NEWSWIRE) --...

Helport AI Opens Office in the Philippines

New ‘Global Center of Excellence’ to Drive Artificial Intelligence...

QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNINGS

Southampton, PA , Jan. 31, 2025 (GLOBE...

Topics

spot_img

Related Articles

Popular Categories

spot_img